A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

September 4, 2024

Primary Completion Date

January 9, 2025

Study Completion Date

September 22, 2025

Conditions
Thyroid Eye Disease
Interventions
BIOLOGICAL

IBI311 (20 mg)

Arm 4: 10 mg/kg IBI311 on Day 1, followed by 20 mg/kg IBI311 from week 3 to week 21, Q3W.

BIOLOGICAL

IBI311 (3-20 mg)

Arm 2: 3 mg/kg IBI311 from day 1 to week 9, Q3W, followed by 20 mg/kg IBI311 from week 12 to week 21, Q3W.

BIOLOGICAL

IBI311 (10 mg)

Arm 3: 10 mg/kg IBI311 from day 1 to week 21, Q3W.

BIOLOGICAL

IBI311 (3-10mg/kg)

Arm 1: 3 mg/kg IBI311 from day 1 to week 9, Q3W, followed by 10 mg/kg IBI311 from week 12 to week 21, Q3W.

Trial Locations (1)

215123

Innovent Biologics (Suzhou) Co. Ltd, Suzhou

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT06525506 - A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease | Biotech Hunter | Biotech Hunter